Biotech companies are often built to be acquired. Perhaps that's a protective mechanism that helps to justify the massive investments required to develop molecules from "works great in mice!" to regulatory approval. Institutional investors, fund managers, and retail investors like you and me generally don't like pouring money into businesses if there's no payoff for years… and years… and years.

Despite a brutal recession that has engulfed the American biotech sector since 2022, the pace of acquisitions has actually been accelerating in recent years. At least 48 drug developers were acquired in 2025 – double the number from 2018 – according to data compiled by BioPharma Dive.

Solt DB crunched the numbers in different ways for additional nerdy insights. For example, investors might wonder what day of the week is the most common for biotech acquisitions?

Most acquisitions were announced on Monday and Tuesday. That makes sense, as publicly-traded companies can more easily set the tone for news flow at the beginning of a week. The general trend held throughout the week, although more acquisitions were announced on Thursday (51) than Wednesday (40).

Whereas there's a clear trend for day of the week and biotech acquisition announcements, the trend isn't so clear when looking at what months of the year are most common for getting scooped up.